For example, in the study of Ciravolo, et al., 2011 [54], it was shown that EVs, in particular exosomes, released from HER2-positive breast cancer cells can bind to Trastuzumab and interfere with its antiproliferative effects on breast cancer cells, thus diminishing its efficacy. Here, ERBB2 is linked to breast cancer.